Market capitalization | $619.69m |
Enterprise Value | $441.39m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 3.39 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-189.21m |
Free Cash Flow (TTM) Free Cash Flow | $-152.02m |
Cash position | $238.43m |
As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.
9 Analysts have issued a Scholar Rock Holding Corp. forecast:
9 Analysts have issued a Scholar Rock Holding Corp. forecast:
Dec '23 |
+/-
%
|
||
Net Profit | -166 -166 |
23%
23%
|
|
Depreciation and Amortization | 2.84 2.84 |
71%
71%
|
|
Stock Compensation | 27 27 |
2%
2%
|
|
Operating Cash Flow | -145 -145 |
9%
9%
|
|
Investments | 0.07 0.07 |
93%
93%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -145 -145 |
9%
9%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the development and discovery of innovative medicines. The company offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Jay Backstrom |
Employees | 150 |
Founded | 2012 |
Website | www.scholarrock.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.